ACOR earnings call for the period ending December 31, 2018.
News & Analysis: Acorda Therapeutics
Even as the market fell again, these stocks posted gains. Find out why.
Wall Street is increasingly concerned about this biotech stock's future.
ACOR earnings call for the period ending September 30, 2018.
Shares retreated after the company provided Wall Street with an updated regulatory timeline. Here's what investors need to know.
Find out which of these companies lost the most ground.
The company could face stiff competition following an unfavorable ruling by an appeals court.
The company's lawyers made a last-ditch effort to save previously invalidated patents for a key drug.
An important player in the neuroscience field appears interested in acquiring the troubled drugmaker.
The company provided an update on one of its lead drug candidates.